HF Sinclair Corporation Common Stock vs Neurocrine Biosciences Inc — how do they compare? HF Sinclair Corporation Common Stock trades at $120.35 (market cap $21.46B), while Neurocrine Biosciences Inc trades at $141.34 (market cap $14.36B). The key difference: HF Sinclair Corporation Common Stock is the larger of the two by market cap, and HF Sinclair Corporation Common Stock pays a 1.74% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HF Sinclair Corporation Common Stock for 0 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DINO | NBIX | |
|---|---|---|
Market Cap | $21.46B | $14.36B |
Volume | 2,430,580 | 1,237,180 |
Sector | Energy | Health |
52-Week High | $120.72 | $185.50 |
52-Week Low | $45.88 | $123.10 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $22.44B | $14.37B |
Dividend Yield | 1.74% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
HF Sinclair refines and markets petroleum products, including gasoline, diesel, and jet fuel. It also operates logistics and renewable fuels businesses.
Read more on DINO →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →